about
Linking F-box protein 7 and parkin to neuronal degeneration in Parkinson's disease (PD)The interhemispheric connections of the striatum: Implications for Parkinson's disease and drug-induced dyskinesiasThe dopaminergic response in multiple system atrophy.Dyskinesias do not develop after chronic intermittent levodopa therapy in clinically hemiparkinsonian rhesus monkeysPost- versus presynaptic plasticity in L-DOPA-induced dyskinesia.A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.Efficacy and safety of levodopa-carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson's disease patients.6-Hydroxydopamine lesions of rat substantia nigra up-regulate dopamine-induced phosphorylation of the cAMP-response element-binding protein in striatal neurons.Polymorphism in candidate genes: implications for the risk and treatment of idiopathic Parkinson's disease.Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label resultsTreatment of Parkinson's disease in the advanced stage.The immunological challenges of cell transplantation for the treatment of Parkinson's disease.Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease.Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa doseResponse to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation.Dual κ-agonist/μ-antagonist opioid receptor modulation reduces levodopa-induced dyskinesia and corrects dysregulated striatal changes in the nonhuman primate model of Parkinson disease.Levodopa and executive performance in Parkinson's disease: a randomized study.Safety and efficacy of levodopa-carbidopa intestinal gel: results from an open-label extension study in Japanese, Korean and Taiwanese patients with advanced Parkinson's disease.Therapy for dyskinesias in Parkinson’s disease patients
P2860
Q26752685-EFB973FE-A041-4F32-AE20-BB29664F8FD4Q26826951-6E544FEC-7CD8-4DD8-A257-A15BBB8EBE30Q28317869-391CACB4-F0FD-48F9-A3B8-F6AC3B671B2AQ30498440-F639F523-7E22-4AD6-BF44-916CECB91932Q33255884-DA047177-80F5-4536-B097-36B09B698934Q33733049-0FFF74A6-10E6-4EB5-9F28-B9BE5E237EA8Q33917449-655CCEEB-ACD1-4A84-8A38-77880C45BED9Q35802353-B9149EB8-7436-4B75-B872-D6052D123DB4Q35821201-08EDEC6D-56CF-4C32-A1A1-AFB79E5CD094Q36318159-A22E3B16-DCAC-476D-83F9-33B8A11A2291Q36361513-F4EF6346-7C84-4FC7-8A01-5957E59FB6D2Q36725292-4E7C8300-1856-4ABB-ACB8-D5BBC9829D6AQ38004257-4A50B707-630D-44B3-AC41-DDC14CBCB18FQ38262418-B53DA133-B27A-4D7E-B925-6C3B96B1012EQ42099300-1E4D2263-95D0-4162-9A58-BB1FC5E41F7CQ44187507-58A63CC8-67BF-4098-AA83-E1074C1200ABQ44350349-CC5D2A21-9621-4495-8C87-8F37D5B267CFQ51949909-0D4317B9-EC58-436F-80D8-81421FB2912CQ53839390-7CB0F07B-2E76-434C-BC50-A3E55CB5FD90Q57518128-EC4E6014-E67C-4197-A4D6-099DF0E44DE5
P2860
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Pathogenesis of dyskinesias in Parkinson's disease.
@en
type
label
Pathogenesis of dyskinesias in Parkinson's disease.
@en
prefLabel
Pathogenesis of dyskinesias in Parkinson's disease.
@en
P2093
P356
P1433
P1476
Pathogenesis of dyskinesias in Parkinson's disease.
@en
P2093
P2860
P304
P356
10.1002/ANA.410250521
P577
1989-05-01T00:00:00Z